ClinicalTrials.gg
CompletedNCT06522113Updated Aug 6, 2024

Cilostazol and Aspirin in Stroke and TIA

A Phase 4 interventional study of Cilostazol and Clopidogrel in Ischemic Stroke and TIA, sponsored by Incheon St.Mary's Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Incheon St.Mary's Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 years after the study started (first participant enrolled Jul 2019, registered Jul 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies testing cilostazol in Ischemic Stroke — 9 open to participants now, 9 under way, 7 of them phase 3. Cilostazol · Ischemic Stroke.

Enrollment
16th of 18
378 · median 848
Started
2019
the only one that year
Phase 4
7 of 18
1 open now
Registered
11th of 18
by date
Lead sponsor
1 of 18
Incheon St.Mary's Hospital

Among the 18 studies testing cilostazol in Ischemic Stroke, this one is the 16th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 4, and was the 11th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

9 of the 18 studies testing cilostazol in Ischemic Stroke are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cilostazol

Cilostazol: first FDA approval 1999 (PLETAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing cilostazol in Ischemic Stroke, or all of them as a file.
02

Study summary

This study is a randomized, open-labelled trial. We randomly assigned patients within 24 hours after the onset of minor ischemic stroke or high-risk TIA to combination therapy with cilostazol and aspirin or to clopidogrel plus aspirin. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis.

Read the detailed description

This study is a randomized, open-labelled trial. We randomly assigned patients within 24 hours after the onset of minor ischemic stroke or high-risk TIA to combination therapy with cilostazol and aspirin (aspirin 100mg with cilostazol 200 mg for 21 days) or to clopidogrel plus aspirin (aspirin 100mg with clopidogrel 75mg for 21 days). The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis. The primary safety outcome was the moderate-to-severe bleeding event according to (GUSTO) definition. The secondary outcomes were new clinical vascular event (ischemic or hemorrhagic stroke, myocardial infarction, or vascular death), analyzed as a composite outcome and also as individual outcomes. Vascular death was defined as death due to stroke (ischemic or hemorrhagic), systemic hemorrhage, myocardial infarction, congestive heart failure, pulmonary embolism, sudden death, or arrhythmia.

03

Conditions studied

  • Ischemic Stroke
  • TIA

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of an acute minor ischemic stroke or
  • Acute minor stroke was defined by a score of 3 or less at the time of randomization on the National Institutes of Health Stroke Scale (NIHSS; scores range from 0 to 42, with higher scores indicating greater deficits)

Exclusion criteria

Exclusion Criteria:

  • Intracerebral Hemorrhage
  • Brain tumor
  • Brain abscess, or other major non-ischemic brain disease;
  • Isolated sensory symptoms (numbness, isolated visual changes, or isolated dizziness or vertigo) without evidence of acute infarction on baseline CT or MRI of the head
  • A score of more than 2 on the modified Rankin scale, immediately before the occurrence of the index ischemic stroke or , indicating moderate disability or worse at baseline
  • An NIHSS score of 4 or more at randomization
  • A clear indication for anticoagulation therapy (presumed cardiac source of embolus, such as atrial fibrillation or prosthetic cardiac valve) or a to clopidogrel, cilostazol or aspirin
  • History of intracranial hemorrhage
  • Anticipated requirement for long-term non-study antiplatelet drugs or for nonsteroidal anti-inflammatory drugs affecting function
  • Heparin therapy or oral anticoagulation therapy within 10 days before randomization
  • Gastrointestinal bleeding or major surgery within the previous 3 months
  • Planned or probable revascularization (any angioplasty or vascular surgery) within 3 months after screening (if clinically indicated, vascular imaging was to be performed before randomization, whenever possible)
  • Planned surgery or interventional treatment requiring cessation of the study drug
  • TIA or minor stroke caused by angiography or surgery
  • Severe non- cardiovascular coexisting condition, with a of less than 3 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
378 participants (actual)

Study arms

  • Active comparator
    aspirin with clopidogrel

    aspirin 100mg with clopidogrel 75mg for 21 days

    Drug: Clopidogrel

  • Experimental
    aspirin with cilostazol

    aspirin 100mg with cilostazol 200 mg for 21 days

    Drug: Cilostazol

Interventions

  • patients were given cilostazol 100mg twice a day with aspirin

    Also known as: aspirin

  • patients were given clopidogrel 75mg with aspirin

    Also known as: aspirin

06

What researchers measure

Primary outcomes

  1. New stroke event for 90 days (Ischemic or hemorrhagic)

    New stroke event for 90 days (Ischemic or hemorrhagic)

    Time frame: for 90 days

  2. Moderate-to-severe bleeding event according to (GUSTO) definition

    Moderate-to-severe bleeding event according to (GUSTO) definition: Moderate : bleeding requiring transfusion Severe : Fatal or intracerebral bleeding, or bleeding resulting in substantial hemodynamic compromise requiring treatment

    Time frame: for 90 days

Secondary outcomes

  1. New clinical vascular event (ischemic or hemorrhagic stroke, myocardial infarction, or vascular death), analyzed as a composite outcome and also as individual outcomes.

    New clinical vascular event (ischemic or hemorrhagic stroke, myocardial infarction, or vascular death), analyzed as a composite outcome and also as individual outcomes. Vascular death was defined as death due to stroke (ischemic or hemorrhagic), systemic hemorrhage, myocardial infarction, congestive heart failure, pulmonary embolism, sudden death, or arrhythmia.

    Time frame: for 90 days

07

Study locations

1 site
  • The Catholic university of korea, Incheon St. Mary's hospital
    Incheon, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Oct 2022, 38 months.

Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's 38 months is above that.

Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2024
First posted
Jul 26, 2024
StartActual
Jul 18, 2019
Primary completionActual
Oct 17, 2022
CompletionActual
Oct 17, 2022
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06522113
Lead sponsor
Incheon St.Mary's Hospital
Responsible party
Taewon Kim (Principal Investigator, Incheon St.Mary's Hospital) — Principal investigator
First posted
Jul 26, 2024
Start date
Jul 18, 2019
Primary completion
Oct 17, 2022
Completion
Oct 17, 2022
Last update
Aug 6, 2024

Study contacts

Taewon Kim, Dr
principal investigator · the catholic university of korea, neurology department

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion